Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for GSK plc (GSK) provides access to the company’s regulatory disclosures as a foreign private issuer. GSK files an annual report on Form 20-F and frequent current reports on Form 6-K under the Securities Exchange Act of 1934. These documents, together with information on American Depositary Shares listed on the New York Stock Exchange, form a key source of official information for investors analyzing GSK stock.
Recent Form 6-K filings include multiple transaction notifications for persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. These reports detail acquisitions of ordinary shares or American Depositary Shares, often through dividend reinvestment plans, share reward plans or the exercise of options under GSK’s share save arrangements, and specify trade dates, prices, volumes and trading venues such as the London Stock Exchange and New York Stock Exchange.
Other 6-K filings report total voting rights, including the number of issued ordinary shares, treasury shares and the resulting total voting rights figure. This information helps shareholders determine whether they must notify changes in their holdings under applicable disclosure rules. Additional 6-K submissions incorporate press releases on significant product approvals, clinical trial results and agreements, such as approvals for Exdensur (depemokimab), Nucala (mepolizumab) in COPD, Shingrix prefilled syringe presentations, and positive phase III results for bepirovirsen in chronic hepatitis B.
On Stock Titan, these filings are complemented by AI-powered summaries that explain the practical meaning of each document. Investors can quickly understand insider dealing reports, changes in capital structure, and major regulatory or clinical events without reading every line of the original filing. Real-time updates from EDGAR ensure that new GSK 6-K submissions, as well as the annual 20-F, appear promptly, while insider transactions analogous to Form 4 in the US domestic context are captured through the PDMR transaction notifications.
By using this page, users can review GSK’s historical and current SEC filings, track patterns in executive and director share dealings, and connect clinical and regulatory announcements to their formal disclosure record, all with the support of AI-generated explanations.
GSK plc reports that executive Maya Martinez-Davis acquired 70.566 American Depositary Shares at $59.5200 each on
GSK plc reports that, on 26 February 2026, it bought 545,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme, at a volume‑weighted average price of 2,186.88p per share.
The shares will be held as treasury shares. After this transaction, GSK holds 243,597,094 shares in treasury and has 4,072,555,332 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 5.98% of voting rights.
GSK reports that China’s National Medical Products Administration has accepted its new drug application for linerixibat for priority review to treat cholestatic pruritus in adults with primary biliary cholangitis, a rare autoimmune liver disease.
The submission is based on the positive phase III GLISTEN trial, where linerixibat showed rapid, significant and sustained improvement in cholestatic pruritus and itch-related sleep interference versus placebo, with a safety profile consistent with earlier studies and its IBAT-inhibitor mechanism. In China, primary biliary cholangitis affects about 280,000 people, and cholestatic pruritus can impact up to 89% of patients over the course of their disease, with few effective treatment options. Linerixibat has Orphan Drug Designation in the US, EU and Japan, and marketing applications are under review in the US, EU, UK and Canada, but it is not yet approved anywhere.
GSK reports that Japan's Ministry of Health, Labour and Welfare has accepted for review a new drug application for bepirovirsen as a treatment for adults with chronic hepatitis B. This is the first regulatory filing globally for the drug and follows positive phase III B-Well trial results showing statistically significant and clinically meaningful functional cure rates when added to standard therapy.
Bepirovirsen, an investigational antisense oligonucleotide, targets hepatitis B viral RNA to reduce viral replication and surface antigen levels, while stimulating the immune system. It has SENKU designation in Japan, which enables expedited review, and has also received Fast Track or similar designations in other major markets, but it is not yet approved anywhere.
GSK plc reports that on 25 February 2026 it repurchased 455,000 ordinary shares of 31¼ pence each through BNP Paribas at a volume-weighted average price of 2,209.58p, with prices ranging from 2,176.00p to 2,217.00p per share.
The shares will be held as treasury shares as part of its existing buyback programme started under a non-discretionary agreement on 17 February 2026, since when 3,161,000 shares have been bought. After this transaction, GSK holds 243,052,094 shares in treasury and has 4,073,100,332 shares in issue and voting rights, with treasury shares representing 5.97% of voting rights.
GSK plc reported that Chief People Officer Diana Conrad acquired American Depositary Shares through a company pension plan. The transaction involved the purchase of 11.163 ADS at a price of CAD 82.8205 per ADS on 2026-02-13 on the New York Stock Exchange.
GSK plc reported that non-executive director Dr Hal Barron acquired additional American Depositary Shares through his GSK 401(k) plan. The purchase resulted from the reinvestment of dividends, leading to the acquisition of 64 ADS at a price of $59.5200 per ADS.
The transaction took place on 2026-02-20 on the New York Stock Exchange (XNYS). This reflects automatic plan-based dividend reinvestment rather than an open‑market discretionary trade.
GSK plc has agreed to acquire Canada-based 35Pharma Inc., a private clinical-stage biopharma company, for $950 million in cash at closing. The deal adds HS235, a potential best-in-class activin signalling inhibitor for cardiopulmonary diseases, to GSK’s pipeline.
HS235 has completed phase I trials in healthy volunteers, with studies starting in pulmonary arterial hypertension and pulmonary hypertension due to heart failure with preserved ejection fraction. GSK highlights HS235’s design to lower bleeding risk and its potential metabolic benefits, aiming to strengthen its Respiratory, Immunology and Inflammation portfolio in a pulmonary hypertension market forecast to reach $18 billion by 2032.
GSK plc reports that, acting through BNP Paribas, it repurchased 477,000 ordinary shares on 24 February 2026 as part of its existing share buyback programme. The shares were bought at prices between 2,175.00p and 2,217.00p per share, with a volume-weighted average price of 2,200.50p, and will be held as treasury shares.
Since 17 February 2026, GSK has repurchased a total of 2,706,000 ordinary shares. After this latest transaction, the company holds 242,597,094 ordinary shares in treasury and has 4,073,555,332 ordinary shares in issue excluding treasury shares, which is also the total number of voting rights. GSK states that treasury shares now represent 5.96% of its voting rights.
GSK plc reported routine insider share transactions for two senior figures under its executive savings plans. Non-Executive Director Dr Hal Barron acquired 2,007.552 notional American Depositary Shares at
On the same date, James Ford, SVP and Group General Counsel, acquired 47.460 notional ADS, also at